These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
521 related articles for article (PubMed ID: 23796888)
1. Molecular mechanisms of muscle atrophy in myotonic dystrophies. Timchenko L Int J Biochem Cell Biol; 2013 Oct; 45(10):2280-7. PubMed ID: 23796888 [TBL] [Abstract][Full Text] [Related]
2. (CCUG) Yenigun VB; Sirito M; Amcheslavky A; Czernuszewicz T; Colonques-Bellmunt J; García-Alcover I; Wojciechowska M; Bolduc C; Chen Z; López Castel A; Krahe R; Bergmann A Dis Model Mech; 2017 Aug; 10(8):993-1003. PubMed ID: 28623239 [TBL] [Abstract][Full Text] [Related]
3. Clinical aspects, molecular pathomechanisms and management of myotonic dystrophies. Meola G Acta Myol; 2013 Dec; 32(3):154-65. PubMed ID: 24803843 [TBL] [Abstract][Full Text] [Related]
4. Dysfunction of protein homeostasis in myotonic dystrophies. Meola G; Jones K; Wei C; Timchenko LT Histol Histopathol; 2013 Sep; 28(9):1089-98. PubMed ID: 23536431 [TBL] [Abstract][Full Text] [Related]
5. Development of Therapeutic Approaches for Myotonic Dystrophies Type 1 and Type 2. Timchenko L Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142405 [TBL] [Abstract][Full Text] [Related]
6. Myotonic dystrophy: emerging mechanisms for DM1 and DM2. Cho DH; Tapscott SJ Biochim Biophys Acta; 2007 Feb; 1772(2):195-204. PubMed ID: 16876389 [TBL] [Abstract][Full Text] [Related]
7. CCUG repeats reduce the rate of global protein synthesis in myotonic dystrophy type 2. Schneider-Gold C; Timchenko LT Rev Neurosci; 2010; 21(1):19-28. PubMed ID: 20458885 [TBL] [Abstract][Full Text] [Related]
8. Muscleblind-like protein 1 nuclear sequestration is a molecular pathology marker of DM1 and DM2. Cardani R; Mancinelli E; Rotondo G; Sansone V; Meola G Eur J Histochem; 2006; 50(3):177-82. PubMed ID: 16920640 [TBL] [Abstract][Full Text] [Related]
9. RNA Foci, CUGBP1, and ZNF9 are the primary targets of the mutant CUG and CCUG repeats expanded in myotonic dystrophies type 1 and type 2. Jones K; Jin B; Iakova P; Huichalaf C; Sarkar P; Schneider-Gold C; Schoser B; Meola G; Shyu AB; Timchenko N; Timchenko L Am J Pathol; 2011 Nov; 179(5):2475-89. PubMed ID: 21889481 [TBL] [Abstract][Full Text] [Related]
10. Skeletal muscle features in myotonic dystrophy and sarcopenia: do similar nuclear mechanisms lead to skeletal muscle wasting? Malatesta M Eur J Histochem; 2012 Aug; 56(3):e36. PubMed ID: 23027352 [TBL] [Abstract][Full Text] [Related]
11. Myotonic dystrophies: An update on clinical aspects, genetic, pathology, and molecular pathomechanisms. Meola G; Cardani R Biochim Biophys Acta; 2015 Apr; 1852(4):594-606. PubMed ID: 24882752 [TBL] [Abstract][Full Text] [Related]
18. Myotonic dystrophy type 2 and related myotonic disorders. Meola G; Moxley RT J Neurol; 2004 Oct; 251(10):1173-82. PubMed ID: 15503094 [TBL] [Abstract][Full Text] [Related]
19. A non-DM1, non-DM2 multisystem myotonic disorder with frontotemporal dementia: phenotype and suggestive mapping of the DM3 locus to chromosome 15q21-24. Le Ber I; Martinez M; Campion D; Laquerrière A; Bétard C; Bassez G; Girard C; Saugier-Veber P; Raux G; Sergeant N; Magnier P; Maisonobe T; Eymard B; Duyckaerts C; Delacourte A; Frebourg T; Hannequin D Brain; 2004 Sep; 127(Pt 9):1979-92. PubMed ID: 15215218 [TBL] [Abstract][Full Text] [Related]
20. Analysis of MTMR1 expression and correlation with muscle pathological features in juvenile/adult onset myotonic dystrophy type 1 (DM1) and in myotonic dystrophy type 2 (DM2). Santoro M; Modoni A; Masciullo M; Gidaro T; Broccolini A; Ricci E; Tonali PA; Silvestri G Exp Mol Pathol; 2010 Oct; 89(2):158-68. PubMed ID: 20685272 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]